ENZ 📈 Enzo Biochem - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2941001024

ENZ: Proteins, Antibodies, Peptides, Small Molecules, Reagents, Kits

Enzo Biochem, Inc., a life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally. The company offers labels, dyes, antibodies, genomic probes, immunoassays, biochemicals, and proteins are used to label, detect, and visualize a biological target of interest in drug discovery exploration and drug development process development. Its proprietary products and technologies play roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. The company licenses its technology. It serves academic researchers, clinical researchers, biotechnology and pharmaceutical companies, and diagnostic manufacturers. Enzo Biochem, Inc. was incorporated in 1976 and is headquartered in Farmingdale, New York. Web URL: https://www.enzo.com

Additional Sources for ENZ Stock

ENZ Stock Overview

Market Cap in USD 56m
Sector Healthcare
Industry Diagnostics & Research
GiC Sub-Industry Health Care Services
IPO / Inception 1980-06-12

ENZ Stock Ratings

Growth 5y -83.3%
Fundamental -45.2%
Dividend 44.4%
Rel. Strength Industry -907
Analysts -
Fair Price Momentum 0.67 USD
Fair Price DCF -

ENZ Dividends

Dividend Yield 12m 13.16%
Yield on Cost 5y 4.17%
Annual Growth 5y %
Payout Consistency 100.0%

ENZ Growth Ratios

Growth Correlation 3m -10.1%
Growth Correlation 12m -57.9%
Growth Correlation 5y -71.8%
CAGR 5y -20.44%
CAGR/Mean DD 5y -0.46
Sharpe Ratio 12m -0.93
Alpha -56.22
Beta 0.53
Volatility 172.09%
Current Volume 450.6k
Average Volume 20d 235k
What is the price of ENZ stocks?
As of December 21, 2024, the stock is trading at USD 0.76 with a total of 450,647 shares traded.
Over the past week, the price has changed by -25.23%, over one month by -22.73%, over three months by -29.15% and over the past year by -41.54%.
Is Enzo Biochem a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Enzo Biochem (NYSE:ENZ) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -45.23 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ENZ as of December 2024 is 0.67. This means that ENZ is currently overvalued and has a potential downside of -11.84%.
Is ENZ a buy, sell or hold?
Enzo Biochem has no consensus analysts rating.
What are the forecast for ENZ stock price target?
According to ValueRays Forecast Model, ENZ Enzo Biochem will be worth about 0.7 in December 2025. The stock is currently trading at 0.76. This means that the stock has a potential downside of -3.95%.
Issuer Forecast Upside
Wallstreet Target Price 5.5 623.7%
Analysts Target Price 5.5 623.7%
ValueRay Target Price 0.7 -3.9%